1098 related articles for article (PubMed ID: 19223699)
1. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A
Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699
[TBL] [Abstract][Full Text] [Related]
2. Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates.
López-Dupla M; Martínez JA; Vidal F; Almela M; Soriano A; Marco F; López J; Olona M; Mensa J
Am J Infect Control; 2009 Nov; 37(9):753-8. PubMed ID: 19487049
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Kim HS; Park BK; Kim SK; Han SB; Lee JW; Lee DG; Chung NG; Cho B; Jeong DC; Kang JH
BMC Infect Dis; 2017 Jul; 17(1):500. PubMed ID: 28716109
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units.
Vojtová V; Kolár M; Hricová K; Uvízl R; Neiser J; Blahut L; Urbánek K
New Microbiol; 2011 Jul; 34(3):291-8. PubMed ID: 21811750
[TBL] [Abstract][Full Text] [Related]
5. In vitro synergistic effect of ciprofloxacin with aminoglycosides against multidrug resistant-Pseudomonas aeruginosa.
Yasmin F; Akhtar N; Hameed A
Pak J Pharm Sci; 2013 Sep; 26(5):1041-4. PubMed ID: 24035966
[TBL] [Abstract][Full Text] [Related]
6. [Antibiotic susceptibility and occurrence of ESBL in Pseudomonas aeruginosa strains isolated from different clinical specimens].
Sacha PT; Jakoniuk P; Wieczorek P; Zalewska M; Leszczyńska K
Med Dosw Mikrobiol; 2004; 56(3):263-73. PubMed ID: 15773503
[TBL] [Abstract][Full Text] [Related]
7. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years].
Nasu Y; Abe M; Ono N; Araki M; Horimi T; Takahashi I
Jpn J Antibiot; 2004 Oct; 57(5):438-48. PubMed ID: 15655905
[TBL] [Abstract][Full Text] [Related]
8. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
9. The peculiarities of Pseudomonas aeruginosa resistance to antibiotics and prevalence of serogroups.
Gailiene G; Pavilonis A; Kareiviene V
Medicina (Kaunas); 2007; 43(1):36-42. PubMed ID: 17297282
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of drug resistance of Pseudomonas aeruginosa and use of antibiotics in burn wards during 6 years].
Dou Y; Zhang Q
Zhonghua Shao Shang Za Zhi; 2014 Feb; 30(1):9-14. PubMed ID: 24684983
[TBL] [Abstract][Full Text] [Related]
11. [Antibiotic resistance and biofilm formation in Pseudomonas aeruginosa strains isolated from patients with urinary tract infections].
Cernohorská L; Sláviková P
Epidemiol Mikrobiol Imunol; 2009 Nov; 58(4):154-7. PubMed ID: 21114003
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.
Tessier F; Quentin C
Eur J Clin Microbiol Infect Dis; 1997 Feb; 16(2):159-62. PubMed ID: 9105845
[TBL] [Abstract][Full Text] [Related]
13. Pseudomonas aeruginosa Antimicrobial Susceptibility Results from Four Years (2012 to 2015) of the International Network for Optimal Resistance Monitoring Program in the United States.
Sader HS; Huband MD; Castanheira M; Flamm RK
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28069652
[No Abstract] [Full Text] [Related]
14. Carbapenemase-producing Pseudomonas aeruginosa in UK.
Woodford N; Palepou MF; Babini GS; Bates J; Livermore DM
Lancet; 1998 Aug; 352(9127):546-7. PubMed ID: 9716067
[No Abstract] [Full Text] [Related]
15. [Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics].
Alişkan H; Colakoğlu S; Turunç T; Demiroğlu YZ; Erdoğan F; Akin S; Arslan H
Mikrobiyol Bul; 2008 Apr; 42(2):321-9. PubMed ID: 18697430
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
[TBL] [Abstract][Full Text] [Related]
17. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality.
Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Macas A; Sakalauskas R
Medicina (Kaunas); 2010; 46(7):490-5. PubMed ID: 20966623
[TBL] [Abstract][Full Text] [Related]
18. Comparison of imipenem and five other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa.
Gerçeker AA; Otük G
Chemotherapy; 1995; 41(5):334-6. PubMed ID: 8521734
[TBL] [Abstract][Full Text] [Related]
19. Pseudomonas aeruginosa: Evaluation of Pathogen Burden and Drug-Resistance Trends in a Tertiary Care Hospital.
Saeed M; Rasheed F; Afzal RK; Hussain S; Riaz S; Ahmad A
J Coll Physicians Surg Pak; 2018 Apr; 28(4):279-283. PubMed ID: 29615167
[TBL] [Abstract][Full Text] [Related]
20. Silver- and fluoride-containing mesoporous bioactive glasses versus commonly used antibiotics: Activity against multidrug-resistant bacterial strains isolated from patients with burns.
Gholipourmalekabadi M; Sameni M; Hashemi A; Zamani F; Rostami A; Mozafari M
Burns; 2016 Feb; 42(1):131-140. PubMed ID: 26603913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
